Ontology highlight
ABSTRACT:
SUBMITTER: Langabeer SE
PROVIDER: S-EPMC7125505 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Langabeer Stephen E SE Faryal Rehman R O'Dwyer Michael M Loingsigh Sorcha Ní SN
Case reports in hematology 20200323
The introduction of tyrosine kinase inhibitors (TKI) has revolutionised the management of patients with chronic myeloid leukemia (CML) over the last twenty years, but despite significant improvements in survival, patients exhibit long-term side effects that impact on quality of life. A major advance in CML management has been the ability to discontinue TKI therapy achieving a treatment-free remission (TFR), yet this option is only available to eligible patients who present with low-risk disease ...[more]